|
Patent landscape, scope, and claims: |
United States Patent 9,675,700 Scope, Claim Coverage, and US Patent Landscape for Waterless Tetracycline Topical Compositions
US 9,675,700 is a formulation-centric, waterless topical composition patent built around (i) a tetracycline antibiotic in a hydrophobic/oil-plus-wax carrier, (ii) strict exclusion of multiple “minocycline-incompatible” solvents, (iii) exclusion of polyols and/or polyethylene glycol, (iv) stability/performance limitations (tetracycline retention, viscosity increase, and spread/liquefy under shear), and (v) downstream use claims covering dermatologic and other surface disorders. The claim set is broad in carrier chemistry (oil class breadth; wax class breadth; gelled-mineral-oil alternative) while narrowing via negative limitations and specific numeric ranges, which together drive design-around strategies for generic entrants and formulation licensors.
What does US 9,675,700 claim for a “waterless tetracycline” topical composition?
Featured snippet answer: The core invention is a waterless topical composition containing a tetracycline antibiotic dispersed in a hydrophobic oil and a wax/fatty alcohol/fatty acid agent, with explicit exclusions for specified solvents (including DMSO and DMF), exclusion of polyols and/or PEG, and performance/stability limitations (notably ≥90% tetracycline retention after 6 months at 25°C and shear-liquefying gel behavior in some dependent claims).
Claim 1: Independent scope-defining elements (largest enforceable perimeter)
Claim 1 requires all of the following:
- Composition is waterless
- Contains a tetracycline antibiotic
- Contains a carrier comprising
- (a) at least one hydrophobic oil
- (b) an agent with the “fatty alcohol/fatty acid/wax” architecture in at least one of the enumerated configurations:
- (i) fatty alcohol + wax
- (ii) fatty acid + wax
- (iii) fatty alcohol + fatty acid + wax
- (iv) a wax comprising hydrogenated oil
- (v) combination of two or more waxes
- Minocycline-incompatible substance exclusion: the composition does not contain any of the listed incompatible substances, including (selected examples from the list provided by you)
- Polar aprotic/protic or polar solvents: DMSO, DMF, acetonitrile, acetone, methyl ethyl ketone, 1,4-dioxane, THF, NMP, pyridine, piperidine, N-methyl-2-pyrrolidone, 1-methyl-2-pyrrolidinone
- Azone (1-dodecylazacycloheptan-2-one)
- Dimethyl isosorbide
- Polyols and polyol-like ingredients: glycerin, ethanol, propylene glycol, butylene glycol, PEG 200, hexylene glycol, PEG 400, diethylene glycol monoethyl ether
- Specific oils/therapeutic excipients in your list: pomegranate seed oil, isostearic acid, and Ethocel (ethylcellulose)
- Negative limitation on polyols/PEG: “does not contain a polyol and/or polyethylene glycol”
- The remaining portions of the claim set expand carrier options and performance constraints without changing the above skeleton.
Enforcement implication: Claim 1 is not limited to minocycline itself. It is a tetracycline platform with minocycline-specific solvent exclusion layered onto the system. That negative limitation is likely to be a key validity and infringement battleground because it narrows compositional freedom more than many “oil + wax” patents.
Claim 2: Stability requirement as a patentability and infringement hook
Claim 2 adds a measurable stability/performance requirement: after storage at 25°C for at least 6 months, the composition retains ≥90% of the tetracycline initially present.
Practical effect: If a competitor achieves the same architecture but with lower retention, they may avoid Claim 2 while still potentially falling within Claim 1.
Claim 3: Rheology under shear (gel liquefies and spreads)
Claim 3 requires the composition be a gel that liquefies and spreads upon shear force.
Practical effect: This is a functional limitation that can be tested (rheology/texture analysis). It may be avoidable via non-gel formats or different flow behavior.
Claim 4: Hydrophobic oil breadth (very large enumerations)
Claim 4 lists a wide class of hydrophobic oils and emollients, including:
- mineral/hydrocarbon oils
- triglycerides and plant/animal oils
- ester oils (including many fatty ester derivatives)
- silicone oils (cyclomethicone, dimethyl polysiloxane, dimethicone, silicone oils with epoxy and fluoro modifications)
- alkanes (isoparaffin, polyalphaolefin, isohexadecane, isododecane)
- synthetic oils (polyisobutylene, synthetic isoalkanes)
- plus mixtures
Enforcement implication: The oil selection is not likely a distinguishing feature in litigation because the claim provides a large enumerated set. The narrower differentiators are the wax/agent architecture and negative solvent/polyol/PEG limitations.
How do dependent claims narrow or broaden US 9,675,700 coverage?
Carrier architecture refinement: fatty alcohol/fatty acid/wax properties
- Claims 5-8: chain length and melting point
- At least one fatty alcohol or fatty acid has ≥12 carbons
- chain substituted with hydroxyl group
- fatty acid example: 12-hydroxy stearic acid
- melting point: >40°C
- Claims 9-12: enumerated fatty alcohols and fatty acids; wax types; “agent comprises fatty alcohol + fatty acid + wax where wax comprises beeswax/hydrogenated oil/both”
- fatty alcohol examples: lauryl, myristyl, cetyl, stearyl, arachidyl, behenyl, tetracosanol, hexacosanol, octacosanol, triacontanol, tetratriacontanol
- fatty acid examples: dodecanoic, tetradecanoic, hexadecanoic, … through long chain saturated acids up to pentatriacontanoic acid
- wax examples range from plant/animal/petroleum derived to hydrogenated oils and hydrogenated castor oil and paraffin wax subranges
Enforcement implication: If accused products use shorter-chain fatty alcohols or waxes with different thermal properties, the entrant may argue non-infringement of these dependent claims while still risking Claim 1 because Claim 1 does not require chain length/melting point.
Explicit wax taxonomy (Claim 10-11)
Wax options include very broad categories and also detailed examples:
- plant waxes, animal waxes, petroleum waxes, vegetable waxes
- hydrogenated oil waxes and hydrogenated castor oil
- paraffin wax options
- polyethylene wax
- lanolin wax, carnauba wax, beeswax, jojoba oil, montan wax, ozokerite, sugarcane wax, and many others
Enforcement implication: Again, the wax list is expansive. Avoidance will more likely target negative limitations (polyol/PEG and incompatible solvents) or the specified component ratios rather than wax identity alone.
Solvent/polarity constraints: Claim 13-16 and 29 and 48-55
Several dependent claims tightly control excipient classes:
- Claims 13-15: less than 0.4% / 0.2% / 0.1% by weight of a system comprising protic solvent + polar aprotic solvent + silicone thickening agent
- Claim 16: less than 0.4% by weight of polymeric gelling agent, polyol, short chain alcohol, and silicone thickening agent
- Claim 29: composition is free of (or has) protic solvent/polar aprotic solvent/polymeric gelling agent/polyol/short chain alcohol/silicone thickening agent
- Claims 48-49: free of surfactants and certain polymers (xanthan gum, poloxamer, carbomer, methocel, sodium CMC)
- Claims 53-55: free of PEG-related surfactant families and poloxamer/xanthan etc; “does not contain either a polyol or polyethylene glycol”; and “does not contain a polar solvent”
- Claims 56: carrier has neutral pH
Enforcement implication: The negative limitation stack is likely the most leverage in infringement analysis. Many competitors use polar co-solvents, PEG surfactants, or polyols for solubilization, stabilization, or spreadability. US 9,675,700 is built to exclude those.
Tetracycline scope and hydrophobic/logP constraints
- Claims 17-23: enumerated tetracyclines include tetracycline, oxytetracycline, demeclocycline, doxycycline, lymecycline, meclocycline, methacycline, minocycline, rolitetracycline, chlorotetracycline, tigecycline
- Claims 18: tetracycline is hydrophobic
- Claims 20: LogP (pH 7 buffer/chloroform distribution constant) ≤0.2
- Claims 21: tetracycline does not comprise hydroxy group at carbon 5, 6, and 7
- Claims 22-23: minocycline and minocycline mixtures; Claim 23 specifically “tetracycline is minocycline”
Enforcement implication: If a product uses a specific tetracycline that fails the LogP or structural exclusion limitation, it may avoid dependent claims even if it still falls under Claim 1 (unless Claim 1 is interpreted to require those parameters via incorporation or necessity, which is not stated in your claim text).
Packaging and foam rheology: Claim 24
Claim 24 adds an aerosol-specific limitation:
- packaged in an aerosol container and pressurized
- on release it affords a foam that breaks upon application of shear force
Enforcement implication: This is avoidable by non-aerosol formats.
Carrier composition exemplars: Claims 25-26
Claims 25 and 26 provide two specific carrier formulations (percent ranges by weight) using:
- soybean oil, coconut oil
- cyclomethicone
- light mineral oil
- cetostearyl alcohol
- stearic acid
- myristyl alcohol
- hydrogenated castor oil
- beeswax
- stearyl alcohol
- behenyl alcohol
Enforcement implication: These are narrower embodiments. A competitor can steer clear of these dependent claims by using different oil/wax ratios, but still risk Claim 1 if the alternative formulation meets the independent architecture and negative limitations.
What methods and use cases does US 9,675,700 cover?
Method of treatment (Claims 59-62)
A method claim applies the composition of Claim 1 to treat “dermatological, ophthalmological, gynecological, or mucosal disorder” where the disorder includes at least one etiological factor among infection, inflammation, oxidative stress, neurodegeneration, or apoptosis.
Claim 60: dermatological disorder examples
A long list includes acne variants, MRSA, bacterial skin infections, psoriasis, rosacea, skin ulcers, burns, viral infections, and more.
Claim 61: gynecological/mucosal disorder examples
Includes body cavities/mucosal surfaces, nose/mouth/eye/ear groups, vagina/urethra/rectum, and infections such as chlamydia, gonorrhea, herpes, HPV, bacterial vaginosis, candidiasis, trichomoniasis, vulvodynia, hemorrhoids, and others.
Claim 62: ophthalmological disorders examples
Includes eye infections, blepharitis, corneal abrasion/ulcer/edema, conjunctivitis, glaucoma, dry eye, trachoma, uveitis, and others.
Enforcement implication: The claim ties treatment to a broad etiological factor set and a broad disorder set. In practice, infringement of method claims often becomes evidence-driven: prescriber instructions, labeling, clinical protocol, and marketing claims.
How does the claim set allocate risk for generics or formulation challengers?
Likely infringement points
- Composition structure: waterless tetracycline + hydrophobic oil + wax and fatty alcohol/fatty acid agent
- Negative limitations:
- incompatible solvent exclusion list
- explicit exclusion of polyols and/or polyethylene glycol
- negative surfactant and polymer exclusions in dependent claims
- Stability/performance (Claim 2, Claim 3, and other functional limitations)
- Aerosol foam behavior (Claim 24 if used)
- Specific quantitative carrier compositions (Claims 25-26 if copied)
Likely design-around pathways
- Replace excluded polar aprotic/protic solvents and polyols with allowed excipients. The allowed space is constrained by “no polar solvent” (Claim 55) and excluded “minocycline incompatible substances” list.
- Maintain the “waterless” requirement while changing rheology so that shear-liquefaction or foam-breaking conditions are not met (avoiding Claims 3 and 24).
- Use different tetracycline forms or tetracyclines that do not meet LogP/structural limitations of dependent claims (Claims 20-21), though Claim 1 still requires the tetracycline antibiotic generally.
- Avoid matching the enumerated dependent carrier compositions (Claims 25-26) and avoid matching the fatty alcohol/fatty acid/wax property dependencies (Claims 5-12).
US patent landscape: what other US patents typically sit around this kind of claim?
Scope note: Your prompt provides the full claim set text for US 9,675,700 but does not provide the patent’s specification, assignee, filing dates, prosecution history, or citations. Without those, a complete “landscape” (continuations, related patents, citation clusters, or prosecution grants) cannot be produced accurately.
What this claim set signals about the broader estate (non-cited, structurally inferred)
Based on the breadth of carrier chemistry and the heavy reliance on negative solvent/polyol/PEG limitations, this patent is positioned at the intersection of:
- tetracycline stability and solubility management in topical vehicles
- avoidance of known tetracycline incompatibilities with specific solvents (and minocycline-specific interactions)
- “waterless gel” delivery systems that liquefy/spread under shear
- oil-wax systems using long-chain fatty alcohols and waxes for barrier and rheology
- formulation exclusion strategies to steer away from PEG and polyol solubilization platforms
In litigation and licensing, the most relevant “adjacent” patents would typically be those claiming:
- alternative carrier systems for tetracyclines (different gels, different wax matrices, different solvent systems)
- stability-specific claims (tetracycline retention criteria under storage)
- rheology/delivery claims (spray foam breakage; shear spreading; viscosity increase)
- use claims for acne/MRSA/dermatologic infections with tetracyclines
Key quantitative claim constraints (useful for validity and infringement checklists)
| Claim |
Limitation |
Numeric/Type constraint |
| 2 |
Storage stability |
≥90% tetracycline retained after 25°C for ≥6 months |
| 13-15 |
Solvent system with silicone thickening |
<0.4%, <0.2%, <0.1% by weight |
| 16 |
Combined exclusion stack |
<0.4% by weight (polymeric gelling agent + polyol + short chain alcohol + silicone thickening) |
| 20 |
LogP distribution constant |
≤0.2 at pH 7 buffer/chloroform |
| 25 |
Example carrier formulation |
Specific % ranges across soybean/coconut/cyclomethicone/mineral oil/cetostearyl alcohol/stearic acid/myristyl alcohol/hydrogenated castor oil/beeswax/stearly alcohol/behenyl alcohol |
| 26 |
Second example carrier formulation |
Alternate % ranges across same components |
| 30-33 |
Viscosity and agent load |
Viscosity ≥100% higher without tetracycline; agent ranges (0.1-40%; then 0.4-18%; then 1-12%) |
| 34-35 |
Tetracycline loading |
0.001-10%; then 0.025-6% by weight |
| 45 |
Water activity (Aw) |
(0.8-0.9) or (0.7-0.8) or <0.7 |
| 46 |
Hydrophobic oil amount |
60-99% by weight |
| 36, 48-49, 51-55 |
Exclusion rules |
thresholds for polymers/surfactants; free of polyol/PEG and polar solvent; free from specific polymers/surfactants |
How strong is the patent estate for US 9,675,700?
Strength factors within the claim text provided:
- Tight negative limitations (long incompatible solvent list; no polyol and/or PEG) tend to be harder to invalidate on obviousness if those exclusions are not taught in the closest prior art.
- Objective stability and rheology parameters (≥90% retention after storage; shear-liquefying gel behavior; foam breaking upon shear) can support both validity and infringement positions when test data exist.
- Carrier chemistry breadth (oil/wax enumerations) increases the likelihood that many “waterless oil-wax tetracycline” products map to Claim 1.
Weakness factors within the claim text provided:
- Broad oil and wax genus is not restrictive; if prior art already covers waterless tetracycline in oil/wax matrices, the distinguishing burden shifts to the negative exclusions and specific performance criteria.
- Several dependent claims read like “specification-driven embodiment claims.” If the independent Claim 1 is construed broadly, design-around may focus on excluding specific functional features rather than changing basic formulation structure.
Key takeaways
- US 9,675,700 is built around a waterless tetracycline topical vehicle with hydrophobic oil + wax/fatty alcohol/fatty acid agent and strict exclusion of specified minocycline-incompatible solvents plus polyols and/or polyethylene glycol.
- The patent’s practical infringement boundary is likely to hinge on the negative limitation stack and testable performance features (notably ≥90% tetracycline retention after 6 months at 25°C in Claim 2).
- Dependent claims add rheology (shear liquefaction), quantitative load limits, Aw range, viscosity enhancement, and specific exemplar carrier compositions, enabling narrower, embodiment-specific enforcement or design-around.
- Without assignee, dates, cited references, and prosecution history, a complete US estate mapping is not possible from the information provided.
FAQs
-
Can a competitor avoid US 9,675,700 by using a different wax type (e.g., paraffin vs beeswax)?
The wax list is broad in Claim 1, so avoidance typically must target the negative limitations (polyol/PEG and incompatible solvents) and/or performance features in dependent claims.
-
Does Claim 1 require minocycline specifically?
No. Claim 1 requires “a tetracycline antibiotic,” while excluding “minocycline incompatible substances” from the composition.
-
What formulation tests matter most for infringement under this claim set?
Tetracycline retention after storage (Claim 2), shear liquefaction/spreading behavior (Claim 3), Aw (Claim 45), viscosity increase (Claim 30), and absence/presence of excluded excipient classes (polyols/PEG; listed solvents).
-
If a product uses PEG or a polyol as a co-solvent, does it automatically fall outside the patent?
The independent claim states the composition does not contain a polyol and/or polyethylene glycol, so inclusion generally undermines meeting Claim 1.
-
Are method-of-use claims limited to acne or MRSA?
No. The method claims cover broad etiological factors (infection/inflammation/oxidative stress/neurodegeneration/apoptosis) and a wide set of dermatological, ophthalmological, gynecological, and mucosal disorders.
References (APA)
- United States Patent No. 9,675,700 (claims text provided in prompt).
More… ↓
⤷ Start Trial
|
